Therefore, in cycle 1, the modifi ed intentionto-treat population comprised 666 patients in each treatment group. Of those patients, 703 (53%) received chemotherapy based on an anthracycline plus cyclophos phamide and 629 (47%) were treated with chemotherapy not based on an anthracycline plus cyclophosphamide (table 1). Baseline characteristics of
patients based on the type of chemotherapy given are shown in the appendix (p 10).